Evidence map›Paper›PMID 40559230›Full record

ArticleMedical sciences (Basel, Switzerland)2025

Twice as Effective? Pressurized Intra-Thoracic Aerosol Chemotherapy: New Frontiers in Pleural Mesothelioma.

Maria Giovanna Mastromarino, Elena Guerrini, Raffaele Guerrieri, Gianmarco Elia, Alessandra Lenzini, Vittorio Aprile, Greta Alì, Stylianos Korasidis, Marcello Carlo Ambrogi, Marco Lucchi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical sciences (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maria Giovanna MastromarinoDivision of Thoracic Surgery, Cardiac, Thoracic and Vascular Department, University Hospital of Pisa, 56124 Pisa, Italy.ORCID 0000-0001-9291-5619
Elena GuerriniDepartment of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, 56124 Pisa, Italy.
Raffaele GuerrieriDepartment of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, 56124 Pisa, Italy.
Gianmarco EliaDepartment of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, 56124 Pisa, Italy.
Alessandra LenziniDivision of Thoracic Surgery, Cardiac, Thoracic and Vascular Department, University Hospital of Pisa, 56124 Pisa, Italy.
Vittorio AprileDivision of Thoracic Surgery, Cardiac, Thoracic and Vascular Department, University Hospital of Pisa, 56124 Pisa, Italy.ORCID 0000-0001-8538-1719
Greta AlìUnit of Pathological Anatomy, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University Hospital of Pisa, 56124 Pisa, Italy.ORCID 0000-0001-9258-3466
Stylianos KorasidisDivision of Thoracic Surgery, Cardiac, Thoracic and Vascular Department, University Hospital of Pisa, 56124 Pisa, Italy.ORCID 0000-0002-8818-6553
Marcello Carlo AmbrogiDivision of Thoracic Surgery, Cardiac, Thoracic and Vascular Department, University Hospital of Pisa, 56124 Pisa, Italy.
Marco LucchiDivision of Thoracic Surgery, Cardiac, Thoracic and Vascular Department, University Hospital of Pisa, 56124 Pisa, Italy.ORCID 0000-0001-9909-6820

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pressurized intra-thoracic aerosol chemotherapy (PITAC) is a novel and promising strategy for the treatment of malignant pleural effusion (MPE). PITAC enables effective pleurodesis while potentially exerting an antineoplastic effect by delivering chemotherapeutic agents as a therapeutic aerosol into the thoracic cavity via a nebulizer. Our preliminary study involved nine patients with unresectable pleural mesothelioma (PM) treated with PITAC. Among them, one case was particularly emblematic for demonstrating notable oncological improvements in addition to well-known palliative benefits. This patient underwent two PITAC procedures, one year apart, without perioperative complications. Redo pleural biopsies from both previous and new sites revealed only fibrous tissue and inflammatory cells, with no evidence of malignancy. Beyond achieving pleurodesis, PITAC-by combining cytotoxic and sclerosing effects-may offer effective local antineoplastic control and represent a promising avenue for enhancing loco-regional therapy in PM.

Indexed as

Antineoplastic AgentsLung NeoplasmsMesotheliomaPleural NeoplasmsAerosolsAgedFemaleHumansMaleMesothelioma, MalignantMiddle AgedPleural Effusion, MalignantTreatment OutcomeAerosolsAntineoplastic Agentslocal antineoplastic controlmalignant pleural effusionmesotheliomapalliative carepleural mesotheliomapressurized intra-thoracic aerosol chemotherapy (PITAC)

Identifiers

PMID40559230
PMCPMC12195480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.